IRX4204

DRUG3 trials

Sponsors

Io Therapeutics

Conditions

Lung Cancer, Nonsmall CellParkinson's DiseasePlaque PsoriasisPlaque Type PsorisisPsoriasis

Phase 1

Study of IRX4204 for Treatment of Early Parkinson's Disease

CompletedNCT02438215

Io TherapeuticsParkinson's Disease

Start: 2014-08-31End: 2015-05-31Updated: 2015-05-12

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

TerminatedNCT02991651

Io TherapeuticsLung Cancer, Nonsmall Cell

Start: 2016-12-07End: 2025-05-09Target: 12Updated: 2025-05-14

Phase 2

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

SuspendedNCT06723171

Io TherapeuticsPlaque Psoriasis, Plaque Type Psorisis, Psoriasis

Start: 2026-03-01End: 2026-04-01Target: 20Updated: 2026-03-03

Related Papers

IRX4204 in combination with erlotinib to target distinct pathways in lung cancer cells.

Journal of Clinical Oncology2017-05-201 citations